Single B cell antibody technologies

Monoclonal antibodies (mAbs) are arguably the most significant class of biologics for use as pharmaceuticals and diagnostics. Many technological concepts exist for the generation and identification of therapeutically relevant mAbs, including the isolation and cloning of immunoglobulin (Ig) encoding...

Descripción completa

Detalles Bibliográficos
Autor principal: Tiller, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102800/
https://www.ncbi.nlm.nih.gov/pubmed/21473940
http://dx.doi.org/10.1016/j.nbt.2011.03.014
_version_ 1783511914451566592
author Tiller, Thomas
author_facet Tiller, Thomas
author_sort Tiller, Thomas
collection PubMed
description Monoclonal antibodies (mAbs) are arguably the most significant class of biologics for use as pharmaceuticals and diagnostics. Many technological concepts exist for the generation and identification of therapeutically relevant mAbs, including the isolation and cloning of immunoglobulin (Ig) encoding genes from single B-lineage cells. This review summarizes various single B cell approaches and describes their use for the discovery of mAbs with potential therapeutic values or in basic research.
format Online
Article
Text
id pubmed-7102800
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71028002020-03-31 Single B cell antibody technologies Tiller, Thomas N Biotechnol Article Monoclonal antibodies (mAbs) are arguably the most significant class of biologics for use as pharmaceuticals and diagnostics. Many technological concepts exist for the generation and identification of therapeutically relevant mAbs, including the isolation and cloning of immunoglobulin (Ig) encoding genes from single B-lineage cells. This review summarizes various single B cell approaches and describes their use for the discovery of mAbs with potential therapeutic values or in basic research. Elsevier B.V. 2011-09 2011-04-05 /pmc/articles/PMC7102800/ /pubmed/21473940 http://dx.doi.org/10.1016/j.nbt.2011.03.014 Text en Copyright © 2011 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Tiller, Thomas
Single B cell antibody technologies
title Single B cell antibody technologies
title_full Single B cell antibody technologies
title_fullStr Single B cell antibody technologies
title_full_unstemmed Single B cell antibody technologies
title_short Single B cell antibody technologies
title_sort single b cell antibody technologies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102800/
https://www.ncbi.nlm.nih.gov/pubmed/21473940
http://dx.doi.org/10.1016/j.nbt.2011.03.014
work_keys_str_mv AT tillerthomas singlebcellantibodytechnologies

Ejemplares similares